ABCSG 22R-QoL

Status: Treatment Phase & Follow-up


A survey conducted on the quality of life of breast cancer patients registered in ABCSG 22R

Coordinating Investigator: Vesna Bjelic-Radisic (Graz/Wuppertal)
Start of study: 07/2019 (national)
Sample size: 600
Sponsor: ABCSG

Description and status:

The ABCSG 22R-QoL is a survey among breast cancer patients who had received hormone therapy to treat their breast cancer and whose data had already been recorded in the ABCSG patient registry “ABCSG 22R”. While in the registry study 22R, the registration of premenopausal patients with hormone-sensitive breast cancer under existing therapy with Nolvadex® and Zoladex® was carried out and corresponding data were collected, the aim of the survey was to investigate long-term quality of life (QoL) outcome including sexual health and fertility concerns in breast cancer survivors. A total of 7 questionnaires on the topics of QoL, sexual health, body perception, as well as specific questionnaires on fertility concerns and QoL after menopause were issued and analyzed. The department of Gynecology at the Medical University of Graz was activated as the leading center. Completed questionnaires of 600 patients were planned to be collected within 36 months. Eleven sites throughout Austria, who had recruited most of the participants for the 22R patient registry agreed to join the survey. Between the survey start in July 2019 until its end on 15 July 2023, a total of 469 questionnaires are issued to patients at 11 sites.



Share on


Top